# Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer

> **NCT00050960** · PHASE3 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 612 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** bexarotene with carboplatin and paclitaxel
- **DRUG:** carboplatin and paclitaxel

## Key facts

- **NCT ID:** NCT00050960
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-05
- **Primary completion:** 2004-07
- **Final completion:** 2005-03
- **Target enrollment:** 612 (ACTUAL)
- **Last updated:** 2012-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00050960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00050960, "Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00050960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*